glp-1 and gip/glp-1 receptor agonists Potential Use of for Respiratory Disorders: Where Are We at? Targeting GLP-1, GIP & GCG
Description
World Health Organization
Most Americans about 92% have health insurance, either at work, through Medicare or Medicaid, or an individual Affordable Care Act (ACA) plan
The results of the PIONEER-3 trial have now been published in the renowned journal Journal of the American Medical Association (JAMA) and are said to be trend-setting for future therapy of type 2 diabetes.
High fill rates of GLP-1 receptor agonist prescriptions in those with mood disorders could indicate that multimorbidity begets more treatment.
